Kornimate/medical-research-clean huggingface dataset:
the effect of experimentally increasing sedentary behaviour on subjective well-being

Conditions: Sedentary Lifestyle; Quality of Life

Summary: this study will explore the causality between outcomes of subjective well-being and sedentary behavior, through experimentally increasing the sedentary behavior levels of active university students. half of the eligible participants will receive a behavioral counseling intervention to increase sedentary behavior over one week, while the other half will receive no instructions. after one week, all participants will receive no instructions and continue to wear the inclinometer for another week.

the relationship between subjective well-being (swb) and sedentary behavior (sb) has been briefly explored. however, the causality of the relationship (i.e., do higher levels of sb cause changes in swb, or vice-versa) has not been fully examined. experimentally increasing sb and observing the potential subsequent effect on swb, in otherwise non-sedentary individuals, may help to determine the causation between sb and swb. an active sample of full-time university students attending western university will be recruited. upon obtaining consent, demographics will be taken. baseline sedentary behavior levels will be confirmed objectively through inclinometer wear for 1-week. upon confirmation of sufficient sedentary/non-sedentary time, participants will complete questionnaires assessing past-week: swb, sb, physical activity, depression, and anxiety questionnaires. participants will also be randomized to either a behavioral counseling intervention group, or a no-contact control group. participants will then continue wearing the inclinometer for 1 week. after the intervention week, participants will complete the questionnaires again, after which all participants will be told to continue daily behavior, and wear the inclinometer for another week. upon completion of this follow-up week, participants will complete questionnaires again.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * full-time student attending western university * able to read and write in english * self-reporting ≥150 minutes/week of moderate-vigorous physical activity exclusion criteria: * self-reporting a mental illness * currently having a physical disability that would prevent walking

Keywords: sedentary behaviour subjective well-being university students
study evaluating the sbi-087 in subjects with systemic lupus erythematosus

Conditions: Lupus Erythematosus, Systemic

Summary: the purpose of this study is to determine the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of sbi-087 in subjects with systemic lupus erythematosus (sle).


Eligibility criteria:
inclusion criteria: * diagnosis of sle (by greater than or equal to 4 american college of rheumatology \[acr\] revised criteria) greater than 6 months before study day 1. * history of a positive antinuclear antibody (ana) titer greater than or equal to 1:160 or equivalent. exclusion criteria: * treatment with more than 20 mg of prednisone per day. * evidence of unstable clinically significant disease (e.g., cardiovascular, cerebrovascular, respiratory, or renal disease, or any other unstable serious disorder) other than sle. * history of cancer (other than resected cutaneous basal and squamous cell carcinoma or in situ cervical cancer) with less than 5 years' documentation of a disease-free state.

Keywords: safety pharmacokinetics
a randomized, double-blind, and placebo-controlled study on the treatments of irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the purpose of this study is to test the efficacy and safety of pinaverium and an herbal medication for irritable bowel syndrome (ibs). pinaverium has been in many countries, but there is no randomized, double-blind, large sample size, and placebo-controlled study on this medication yet. tong xie yao fang (formula for pain and diarrhea) is a historically and contemporarily used traditional chinese medicine that can be used for ibs. the hypothesis is that the two remedies are effective and safe for ibs treatment when tested by modern clinical standards and criteria.

pinaverium bromide (pinaverium), an antispasmodics, is one of the most commonly used ibs medication worldwide. however, original clinical studies on pinaverium are scarce. only five original clinical studies from europe, one from latin america, and one from asian were found. these studies were single-centered and small sample sized (19 - 53 ibs patients) studies. tong xie yao fang has long been used in china. its efficacy and safety has not been evaluated by modern scientific method. this study is designed to evaluate the efficacy and safety of pinaverium and tong xie yao fang for ibs treatment in a double-blind, randomized, and large sample size clinical trial using placebo as a control.

Eligibility criteria:
inclusion criteria: * 18 to 70 years old age group, male and female * in accordance with the above western medicine rome iii standards. * in accordance with the above description of deficient spleen qi and liver qi stagnation * informed consent for treatment * no change in appetite during treatments periods exclusion criteria: * pregnant or lactation female patients, and fertility male patients * present digestive system disease within current three months * take ibs medicines within ten days prior to treatment or during treatment * take depression medicine within ten days prior to treatment or during treatment * take pain reliever medicine within ten days prior to treatment or during treatment * have serious primary heart, liver, kidney, lung and blood system diseases, asthma, and lung and liver dysfunction patients * if an emergency occurs; a physician terminates the treatment * cannot comply with the rules and cannot cooperate

Keywords: irritable bowel syndrome, pinaverium herbal medication for ibs, tong xie yao fang (formula for pain and diarrhea)
using artificial intelligence (ai)-assisted pulse diagnosis analysis on precision critical medicine.

Conditions: ICU Patients; Shock

Summary: precision/personalized medicine becomes an important part of modern medical system in the recent years. in the past, the treatments for patients have been decided by doctors according patients' symptoms and/or regular biochemical profiles. however, it is not uncommon that patients' condition varies tremendously even they have same diagnosis, and under such condition, treatment efficacy may be limited due to the heterogeneity among patients. therefore, lack of therapeutic efficacy may be not really ineffective, and the main reason may be inadequate patient classification. for this reason, the "omics"-based personal/precision medicine emerges recently and becomes more and more important. however, in contrast to feasible and common "personalized" medicine, the approach of precision medicine to the molecular medicine level is still difficult, especially among patients in intensive critical units (icus). in contrast to cancer, which has remarkable advances in the past decades, the precision/personal medicine is more difficult in critical and emergent medicine. one reason is the amount of omics data is quite huge and thus dealing with omics data is time consuming. therefore, it is not effective in daily clinical practice in icus care. for this condition, the investigators propose that the combination of clinical data, including pulse diagnosis by traditional chinese medicine (tcm) doctor or answatch wrist sphygmomanometer, fluid responsiveness by "masimo" radical-7 pulse co-oximeter, and the specific database from monitors in icus may be a feasible way to predict outcome among icu patients. there are two main goals for this study: (1) after establishing clinical traditional chinese medicine (tcm) pulse diagnosis and icu clinical parameters databases, acquiring and features of pulse diagnosis by applying ai and (2) analyzing the correlations between the features of pulse diagnosis and important clinical parameters.


Eligibility criteria:
inclusion criteria: * 1.the patient in icu is willing to participate in the research project or patient's family member is willing patient to participate in the research project. * 2.acute circulatory failure exclusion criteria: * 1. the patient do not want to participate in the research project or patient's family member do not want the patient to participate in the research project. * 2. pregnant woman. * 3. goals of treatment is palliative care. * 4. patient is heritable immunodeficiency or acquired immunodeficiency. * 5. known existing cardiac arrhythmia, valvular heart disease, right ventricular dysfunction, intra-cardiac shunt, air leaking from chest drains, abdominal compartment syndrome.

Keywords: traditional chinese medicine pulse diagnosis artificial intelligence precision critical medicine
t1-t2 breast cancer: comparison between removal and preservation of axillary lymph nodes (sinodar one)

Conditions: Breast Cancer

Summary: italian multicentric non inferiority two-arm randomized clinical trial to verify that the experimental treatment (omission of axillary lymph node intervention) in the presence of sentinel lymph node metastases does not lead to a significant worsening in survival or in the risk of locoregional recurrence compared to standard treatment (removal of i-ii level of axillary lymph nodes).

detailed description: the trial is a non-inferiority trial; patients, depending on intra-operative or post-operative sentinel lymph node assessment, are randomly assigned to one of the two intervention groups: group 1: removal of i-ii level of axillary lymph nodes (standard treatment). removal of at least 10 lymph nodes is recommended. group 2: no axillary lymph nodes dissection (experimental treatment). patients for whom sentinel lymph node cannot be found, will undergo complete dissection of the axillary cavity as required by international guidelines. after surgery, according to their bio-pathological profile and to the international guidelines criteria, patients will be able to receive: * no further treatment * complementary radiotherapy * adjuvant medical therapy (chemo and / or hormone therapy). patients will be checked for at least 5 years in the following ways: * six-monthly clinical examination for the first 5 years and yearly thereafter * mammography + annual breast ultrasound * annual axillary ultrasound in cases not subjected to dissection.

Eligibility criteria:
inclusion criteria: * age: 40 ≤75 years old * breast cancer with infiltrating histology * tumor size ≤50 mm (t1 - t2) * clinically and ultrasound node-negative (cn0) breast cancer * no distant metastases (m0) * no neoadjuvant therapy * negative history of previous infiltrating neoplasm * maximum number of metastatic sentinel lymph nodes: 2 * lymph node macro-metastases \> 2mm exclusion criteria: * pregnancy or breastfeeding in progress * inflammatory breast cancer * breast cancer in situ * synchronous contralateral breast cancer * co-morbidities such as to preclude the possible use of adjuvant therapy * conditions that make it impossible to carry out a regular follow-up * other malignancies within the previous 3 years (except carcinoma in situ of the uterine cervix, basalioma or squamous cell ca or non-melanoma skin ca) * breast cancer with non-infiltrating or inflammatory histotype * tumor size\> 50 mm * no sentinel lymph nodes identified * no positive sentinel lymph nodes (pn0) * positive sentinel lymph node number \> 2 * lymph node micro-metastases \<= 2

Keywords: axillary dissection, axillary lymph preservation
preoperative tranexamic acid (txa) to prevent bleeding in patients undergoing major colorectal surgery

Conditions: Bleeding; Colorectal Disorders; Thromboembolism; Tranexamic Acid

Summary: the goal of this prospective pragmatic randomized clinical trial is to determine if preoperative administration of tranexamic acid (txa) reduces bleeding during and after major colorectal surgery. the primary questions are: * does txa reduce bleeding during and after surgery (change in hemoglobin from before surgery to lowest value after surgery within 30 days) * does txa reduce bleeding complications within 30 days of surgery (blood transfusion, return to the operating room or procedural intervention for bleeding, death due to bleeding) * does txa increase the risk of thromboembolic complications within 30 days of surgery (cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism) researchers will compare preoperative txa to no txa to answer the above questions. participants who receive txa will receive 1 g txa iv at the beginning and end of surgery in the operating room.


Eligibility criteria:
inclusion criteria: 1. adults 18 years or older 2. undergoing elective or non-elective inpatient abdominal and pelvic colorectal surgery exclusion criteria: 1. creatinine clearance less than 30 ml/minute 2. long-term dialysis 3. known defective color vision (color blind) 4. pregnancy 5. history of venous or arterial thromboembolism, or active thromboembolic disease 6. disseminated intravascular coagulation (dic) - clinically suspected and/or confirmed by platelet count on cbc, fibrinogen, inr and ptt.

Keywords: tranexamic acid txa bleeding colorectal surgery thromboembolism
myocardial salvage assessed by cardiovascular magnetic resonance - impact on outcome

Conditions: ST-Elevation Myocardial Infarction

Summary: in acute myocardial infarction cardiovascular magnetic resonance imaging can retrospectively detect the myocardium at risk and the irreversible injury. this allows for quantifying the extent of salvaged myocardium after reperfusion as a potential strong end point for clinical trials and outcome. the aim of the present study is to determine the prognostic significance and determinants of myocardial salvage assessed by cmr in reperfused st-elevation myocardial infarction (stemi).


Eligibility criteria:
inclusion criteria: * st-elevation myocardial infarction \< 12 hours * primary percutaneous coronary intervention exclusion criteria: * previous myocardial infarction * prior fibrinolysis * contraindications to cmr at study entry (such as implanted pacemakers, defibrillators, claustrophobia or metallic intracranial implants)

Keywords: myocardial salvage cardiovascular magnetic resonance magnetic resonance imaging myocardial infarction prognosis
anatomical radiofrequency ablation for small hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the aim of this study is to investigate therapeutic outcomes of anatomical radiofrequency ablation for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes.


Eligibility criteria:
inclusion criteria: * child-pugh class a or b7. * presence of chronic hepatitis b or liver cirrhosis. * patients with hepatocellular carcinomas diagnosed by histopathology or noninvasive imaging-based diagnosis according to the korean liver cancer association-national cancer center korea guidelines. * patients with viable hepatocellular carcinoma after locoregional treatment diagnosed by the liver imaging reporting and data system. * tumor location is less than 5 cm from liver capsule. exclusion criteria: * the number of tumor is three or more. * tumor size is over 3 cm. * tumor location is over 5 cm from liver capsule. * child-pugh class b8-9 or c. * presence of macrovascular invasion and/or distant metastasis. * platelet count \ 1.5 (prothrombin time \>1.5 × normal).
swemami dmi, microbiome

Conditions: Type 1 Diabetes

Summary: dysbiosis is associated with an increased risk of preeclampsia during pregnancy. the microbiome differs between those with and without type 1 diabetes and the cause of type 1 diabetes has been associated with dysbiosis. increased knowledge of the microbiome and its variation, depending on the state of health during pregnancies complicated with type 1 diabetes, could in the future lead to preventive care and treatments during these pregnancies.

prospective cohort. all women with type 1 diabetes that are planning a pregnancy and being cared for at the diabetic ward at södersjukhuset will be asked to participate, n= 55. all pregnancies complicated with type 1 diabetes that are being cared for at the special maternity ward at södersjukhuset, n=45. the expected to include is 100. expected viable pregnancies: 50. the maternal vaginal, fecal and oral microbiome will be sampled by "self-sampling" at home before, during and after the pregnancy, by this schedule: 1. inclusion, before pregnancy after an appointment with the diabetic doctor or nurse. or at the first visit at the special maternity care ward during pregnancy (around gestational week 8). 2. when the pregnancy is first discovered if the inclusion were before pregnancy. 3. week 28. 4. when attending delivery ward in labor 5. 6-10 weeks postpartum from both the mother and the new-born. the tests will be sent to the obstetric research center at södersjukhuset, where the tests will be saved in freezes. the analysis will be performed at ctmr at the karolinska institute. background, pregnancy and delivery data will then be associated with the woman microbiome in the vagina, in feces and in saliva.

Eligibility criteria:
inclusion criteria: * pregnant women with type 1 diabetes * included as a patient at women's clinic soderhospital in stockholm * acceptant to sample her microbiome during pregnancy exclusion criteria: * women without type 1 diabetes

Keywords: type 1 diabetes microbioma maternal and fetal pregnacy outcomes
magnetic resonance elastography in hydrocephalus

Conditions: Hydrocephalus

Summary: the purpose of this project is to assess the utility of a new magnetic resonance technique called magnetic resonance elastography (mre) in the non-invasive diagnosis of normal pressure hydrocephalus. the investigators hypothesize that mre produces a unique imaging signature for hydrocephalus that distinguishes the disease from the normal (non-hydrocephalic) but atrophied brain, a distinction not possible with conventional mr imaging studies that are presently available.


Eligibility criteria:
inclusion criteria: * age \>21; * one or more of the following complaints: memory loss/dementia, urinary incontinence, or progressive gait disturbance * ventriculomegaly defined as temporal horn width \>2 mm or a fh:id ratio\>30% on computed tomography or mri, where fh is the maximal distance between the frontal horns and id is the internal diameter from inner table to inner table of the skull at this level (greenberg) * a diagnosis of any adult onset hydrocephalus (nph, post-traumatic, post-hemorrhagic, obstructive, or idiopathic) will be considered for enrollment in this study exclusion criteria: * implanted neuro-stimulator or cardiac pacemaker * known coagulopathy; major organ dysfunction * end-stage congestive heart failure * oxygen-dependent pulmonary disease, hepatic cirrhosis, or dialysis- dependent renal failure; or other condition which, according to the assessment of the treating surgeon or anesthesia team * precludes consideration of elective surgery * patients who may be pregnant will be excluded from this study as well

Keywords: hydrocephalus
postural control in breast hypertrophy

Conditions: Hypertrophy; Sensation Disorders

Summary: principles of motor control suggest that breast hypertrophy can lead to sensoriomotor alterations and impairment in body balance due to postural misalignment. the investigators conducted this study to evaluate the postural control with different sensorial information condition in women with breast hypertrophy.

up to the moment, changes caused by breast hypertrophy are described based on the alteration of body mass distribution leading to an impact of psychological and physical aspects. however, the investigators hypothesize that due to alterations in postural alignment, sensoriomotor inputs are also impaired and postural or motor control are ultimately compromised.

Eligibility criteria:
inclusion criteria: * for the breast hypertrophy group, the women had to be in attendance in the department of plastic surgery and department of gynecology of clinical hospital. exclusion criteria: * for both groups: * rheumatic, neurological, respiratory and vestibular conditions due to possible balance alterations

Keywords: hypertrophy breast postural balance
adjuvant growth therapy in in vitro fertilization

Conditions: Infertility

Summary: in an in vitro fertilization (ivf) cycle super ovulating drugs (gonadotropins) are usually taken to stimulate the ovaries to produce more than one egg. in vitro fertilization protocols are constantly under review in order to improve the recruitment of the follicles, which contain the eggs, whilst minimizing the doses of gonadotrophins required, with the ultimate aim of increasing the live birth rate.

the addition of growth hormone, which is a biological hormone that can be synthetically produced, as a supplement to gonadotrophins in an in vitro fertilization cycle has been suggested as a way in which in vitro fertilization pregnancy rates may be increased.growth hormone has been shown, in animal and human studies, to be important in the recruitment of follicles.however, to date, only a limited number of clinical studies have been performed in order to assess whether the addition of growth hormone can improve the probability of pregnancy in women undergoing ovarian stimulation for in vitro fertilization. as the total number of patients analysed in these studies was small it has not been possible to determine whether if there is any improvement the outcome of an in vitro fertilization cycle when a woman is given growth hormone therapy as a supplement during her treatment. this goal of this study is to determine the effectiveness of using growth hormone therapy as a supplement to the administration of gonadotropins in an antagonist in vitro fertilization protocol.

Eligibility criteria:
inclusion criteria: * women between the ages of 35 to 42 * primary or secondary infertility) * no previous treatment ivf cycle using the same proposed protocol * negative pregnancy test at randomization (urine or blood) exclusion criteria: * contraindication to saizen® * simultaneous participation in another clinical trial * follicle stimulating hormone \> 12 iu/l and/or anti-mullerian hormone \< 0.5 pg/ml * body mass index ≥ 35 kg/m2 * known risk of gestational diabetes * administration of any investigational medication three months prior to study enrolment * positive results of screening for either partner for hiv antibodies, hepatitis b (other than surface antibodies present after vaccination) or hepatitis c * not able to communicate in french or english

Keywords: in vitro fertilization antagonist protocol growth hormone